Noninferiority of antibody response to human papillomavirus type 16 in subjects vaccinated with monovalent and quadrivalent L1 virus-like particle vaccines.
The incorporation of multiple antigens into a single human papillomavirus (HPV) vaccine may induce immune interference. To evaluate whether interference occurs when HPV type 16 (HPV16) virus-like particles are combined in a multivalent vaccine, we conducted a study to evaluate anti-HPV16 responses among subjects receiving three-dose regimens of either a monovalent HPV16 vaccine or a quadrivalent HPV (types 6, 11, 16, and 18) vaccine.
Garland
Suzanne M
SM
Microbiology and Infectious Diseases Department, Royal Women's Hospital, Carlton, University of Melbourne, Melbourne, Victoria, Australia.
Steben
Marc
M
Hernandez-Avila
Mauricio
M
Koutsky
Laura A
LA
Wheeler
Cosette M
CM
Perez
Gonzalo
G
Harper
Diane M
DM
Leodolter
Sepp
S
Tang
Grace W K
GW
Ferris
Daron G
DG
Esser
Mark T
MT
Vuocolo
Scott C
SC
Nelson
Micki
M
Railkar
Radha
R
Sattler
Carlos
C
Barr
Eliav
E
D000293:Adolescent; D000328:Adult; D000914:Antibodies, Viral / Q000096:biosynthesis; D000917:Antibody Formation / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D052162:Human papillomavirus 16 / Q000276:immunology*; D006801:Humans; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000008:administration & dosage / Q000145:classification* / Q000276:immunology*
D000914:Antibodies, Viral; D053918:Papillomavirus Vaccines